Mayo Clinic
The purpose of this study is to determine if oral dronabinol prior to sleep can improve CPAP adherence and sleep quality in humans. We also seek to determine if combination therapy of CPAP and pre-sleep dronabinol is associated with improved BP regulation. We will also explore BP regulatory mechanisms and whether these are impacted differently between traditional CPAP therapy and combination CPAP/dronabinol.
Inclusion Criteria * 21 - 70 years of age * Biological male or female * AHI between 15 - 50 events/hour * Current or new OSA diagnosis * Established or new (within 1 month) CPAP therapy Exclusion Criteria * BMI \> 35 kg/m2 * Diagnosed psychiatric disorders * Hypotension * History of seizures * History of substance abuse or recreational drug use or positive urine drug screen * History of uncontrolled disease including: * Cardiovascular * Pulmonary * Gastrointestinal * Pancreatic * Hepatic * Renal * Hematological * Endocrine (including Type I Diabetes) * Neurological * Ur…
10 mg dose of Dronabinol daily for 6 weeks
10 mg dose of Placebo daily for 6 weeks
Arctuva estimate
Verify or correct the compensation shown for this listing.